<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60912">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02312960</url>
  </required_header>
  <id_info>
    <org_study_id>16996</org_study_id>
    <secondary_id>2014-002407-25</secondary_id>
    <nct_id>NCT02312960</nct_id>
  </id_info>
  <brief_title>Radium-223 Dichloride Long-term Follow-up Program</brief_title>
  <official_title>A Phase 4 Long-term Follow-up Study to Define the Safety Profile of Radium-223 Dichloride</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients will be followed up in this study after prior treatment with BAY 88-8223 /
      Radium-223 dichloride / Xofigo .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This long-term follow up study will enroll subjects who will be transferred from selected
      interventional, company sponsored trials with radium-223 dichloride (feeder trials).

      The primary objectives are to define the long term safety profile of radium-223 dichloride
      (for up to 7 years after the last dose of radium-223 dichloride); to assess the incidence of
      leukemia, myelodysplastic syndrome, aplastic anemia, and primary bone cancer or any other
      new primary malignancy; and, in subjects who receive cytotoxic chemotherapy, to assess the
      incidence of febrile neutropenia and hemorrhage during their chemotherapy treatment and for
      up to 6 months thereafter at a frequency based on local clinical practice.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2014</start_date>
  <completion_date type="Anticipated">September 15, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2025</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of radium 223 dichloride related Adverse Events (AEs)</measure>
    <time_frame>Up to 7 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of radium 223 dichloride related Adverse events (AEs)</measure>
    <time_frame>Up to 7 years</time_frame>
    <description>Severity will be measured as per guidelines by Common Terminology Criteria for Adverse Events; Version 4.03 (CTCAE)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of radium 223 dichloride related Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 7 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of leukemia</measure>
    <time_frame>Up to 7 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of myelodysplastic syndrome</measure>
    <time_frame>Up to 7 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of aplastic anemia</measure>
    <time_frame>Up to 7 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of primary bone cancer</measure>
    <time_frame>Up to 7 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of any other new primary malignancy</measure>
    <time_frame>Up to 7 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of febrile neutropenia in subjects who receive cytotoxic chemotherapy</measure>
    <time_frame>Up to 7 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of hemorrhage in subjects who receive cytotoxic chemotherapy</measure>
    <time_frame>Up to 7 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of deaths</measure>
    <time_frame>Up to 7 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Neoplasm Metastasis / Bone and Bones</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The subjects previously enrolled in a selected radium-223 dichloride feeder trial, their treating health care professional, or caregiver will be contacted in 6-month intervals for follow up and query.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data Collection</intervention_name>
    <description>No study treatment will be provided in this long term follow up study.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject was previously enrolled in a selected company sponsored feeder trial, and has
             received at least 1 dose of radium 223 dichloride or placebo in the feeder trial

        Exclusion Criteria:

          -  Not applicable to this follow up study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <email>clinical-trials-contact@bayer.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Freiburg im Breisgrau</city>
        <state>Baden-Württemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Tübingen</city>
        <state>Baden-Württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89091</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Rostock</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>18107</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Aachen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Jena</city>
        <state>Thüringen</state>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10719</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Bremen</city>
        <zip>28277</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kfar Saba</city>
        <zip>4428164</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Petah Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Forlì</city>
        <state>Emilia-Romagna</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Obninsk</city>
        <zip>249036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 3, 2017</lastchanged_date>
  <firstreceived_date>December 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Succinylcholine</mesh_term>
    <mesh_term>Radium Ra 223 dichloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
